IRVINE, CA, and HERSTAL, BELGIUM – October 5, 2015 – MDxHealth SA (Euronext: MDXH.BR), today announces that it has strengthened its Board of Directors with the appointment of Mr. Walter Narajowski, a medical diagnostics business leader with over 25 years of industry experience.
Mr. Narajowski brings significant experience to MDxHealth in the launch and successful global commercialization of molecular diagnostics from across the industry, from infectious diseases to food safety. He is currently Senior Vice President / General Manager of Roka Bioscience, a molecular diagnostic company developing tests and instrument systems for the food industry. Prior to Roka, Mr. Narajowski was Chief Executive Officer of Pathway Diagnostics, a biomarker development and testing company, which was subsequently sold to Quest Diagnostics.
For the majority of his career, Mr. Narajowski was with Abbott Laboratories where he served in a number of key positions, including Vice President, General Manager of Critical Care Products, Vice President, General Manager of Abbott’s infusion pump business, and General Manager of Physician Office Diagnostics, and Director of Research and Development in Abbott Diagnostics. Mr. Narajowski received his MS in bioengineering from the University of Utah, and his BS in electrical engineering from the Illinois Institute of Technology.
The Company also announces that Mr. Mark Myslinski has stepped down from the Board after five years of dedicated service to MDxHealth.
Mr. Edward L. Erickson, Chairman of the Board of MDxHealth, commented: “We are delighted to have attracted such an accomplished and experienced diagnostics industry leader to our Board. Walter will be integral to guiding MDxHealth as we grow our global commercial presence and bring new tests to market.
“On behalf of the Board, I thank Mark for his many contributions to MDxHealth. His experience has been vital as we evolved from a research-focused company to become a successful commercial business. We wish him well in all of his future endeavors.”
As a result of the aforementioned changes, the MDxHealth Board now consists of:
Greenlands Consulting L.L.C., represented by Mr. Edward L. Erickson, Chairman of the Board of Directors and Independent Director
Dr. Jan Groen, Chief Executive Officer and Executive Director
Mrs. Ruth Devenyns, Independent Director
Lab Dx L.L.C., represented by Mr. Walter Narajowski, Independent Director
Gengest BVBA, represented by Mr. Rudi Mariën, Non-Executive Director
Valiance Advisors LLP, represented by Mr. Jan Pensaert, Non-Executive Director
Following the recent acquisition of NovioGendix, Prof. Dr. Jack Schalken will also serve as an independent advisor to the Company and the Board of Directors.
MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation (epigenetic) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
| For more information:
Dr. Jan Groen, CEO
US: +1 949 812 6979
BE: +32 4 364 20 70
Amber Fennell, Chris Welsh, Hendrik Thys (PR & IR)
Consilium Strategic Communications
UK: +44 20 3709 5701
Cell: + 44 7739658783
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.